Amgen (AMGN)

This morning Amgen (AMGN) is buying Onyx Pharmaceuticals (ONXX)for $125 in cash. So the $64,000 question is did Amgen overpay? We use the scorecard and our upper bound to answer this question. The answer is …

Company Information

Company: ONYX PHARMACEUTICALS INC
Sector: Health Care
Industry: Biotechnology
Market Cap: $9,566 (Millions)

Targets

Price %Gain
Current Price $132.21
Price Target $104.15 -21.2%
Upper Bound $143.72 8.7%
Lower Bound $75.47 -42.9%

Fundamental Variables

P/E Ratio N/A
Sales Growth 12.9%

Valuation Variables

Past Current Future
Profitability (CFROI) 5.3% -1.0% 3.7%
Growth (in Assets) 13.5% 2.1% 2.0%
Color Legend
Company
Rating
Company
Rank
Excellent Top 10%
Good 11- 30%
Average 31- 70%
Fair 71- 90%
Poor Bottom 10%

Stock data last updated 18-AUG-13.

Data provided by Ativo Research LLC. All information provided “as is” for informational purposes only, not intended for trading purposes or advice. Ativo Research LLC is not liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing this page, you agree not to redistribute the information found herein.

Be Sociable, Share!